REPLIGEN CORP acquired Refine Technology, LLC for ~$24.5 million upfront ($20.5M cash + Repligen stock) plus up to $8.75M milestones and a capped royalty up to $2.15M, a transaction completed in June 2014, structured as combination (cash plus stock) with contingent milestones.
Refine Technology, LLC operates in Filtration, is based in Hanover, New Jersey, USA. Acquisition of Refine Technology's business, centered on the market-leading ATF (Alternating Tangential Flow) System used by biopharmaceutical manufacturers for perfusion cell culture. Repligen called it a significant step toward building a best-in-class bioprocessing company.
Herlihy said the deal was 'the acquisition of the market-leading ATF product line used by biopharmaceutical manufacturing customers worldwide,' and that 'the significant overlap of Refine's customer base with our own will support a global buildout of our commercial infrastructure.'
Market-leading ATF perfusion product with strong customer overlap. Customer-base overlap supporting commercial-infrastructure buildout. Repligen Filtration franchise
The significant overlap of Refine's customer base with our own will support a global buildout of our commercial infrastructure.Walter C. Herlihy, Ph.D., President and CEO, Repligen
Advisory firms were not disclosed for this transaction.